Clinical trial
Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes…
NCT00139594 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00139594 |
|---|---|
| Title | Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder |
| Official title | A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug |
| Interventions | licarbazepine |
| Enrollment | 181 |
| Start date | Dec 1, 2004 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Aug 31, 2005 |
| Last update posted | Mar 28, 2017 |
| Countries | Austria, Canada, Colombia, Czechia, Germany, Guatemala, Peru, Russia, Slovakia, South Africa, Ukraine, United States and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: